Status:
COMPLETED
The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
Lead Sponsor:
Shandong University
Collaborating Sponsors:
Taian City Central Hospital
Dezhou People's Hospital
Conditions:
Helicobacter Pylori
Eligibility:
All Genders
18-70 years
Brief Summary
The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacte...
Detailed Description
Helicobacter pylori (HP) infection is a common global infectious disease, which is an important cause of chronic gastritis, peptic ulcer and gastric cancer. At present, due to the non-standard Helico...
Eligibility Criteria
Inclusion
- Patients, aged between 18 and 70 years old, with positive H. pylori infection that was eradicated by previous therapies but failed are included. The H. pylori infection is confirmed by the positive rapid urease test or 13C-breath test.
Exclusion
- Patients with significant underlying disease including liver, cardiac, pulmonary, and renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, the use of PPI, NSAID or antibiotics during the 4 weeks prior to enrolment, and previous history of allergic reactions to any of the medications used in this protocol. Patients previously treated with H. pylori eradication regimens or those unwilling to participate in the study were also excluded.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
820 Patients enrolled
Trial Details
Trial ID
NCT04810793
Start Date
July 1 2020
End Date
June 30 2022
Last Update
October 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 257000